No connection

Search Results

Corporate Score 25 Neutral

Ardelyx CEO Sells 41,666 Shares in $243,000 Transaction

Apr 03, 2026 15:31 UTC
ARDX
Short term

Ardelyx's CEO Michael Raab sold 41,666 shares of the company's stock for approximately $243,000 at $5.84 per share on March 16, 2026. The sale, part of a 10b5-1 trading plan, represents 2.21% of Raab's direct holdings.

  • Michael Raab sold 41,666 shares of Ardelyx for $243,000 on March 16, 2026.
  • The transaction represented 2.21% of Raab's direct holdings, leaving him with 1,816,448 shares.
  • The sale was conducted under a 10b5-1 trading plan, following a similar transaction in February 2026.
  • Ardelyx's stock has gained 6.8% year-over-year but has dropped 16.57% over five years.
  • The company recently appointed Dr. Rajani Dinavahi as Chief Medical Officer.
  • Analysts have a $16.10 average price target for Ardelyx stock, suggesting 170% potential upside.

Ardelyx President and CEO Michael Raab executed a stock sale of 41,666 shares on March 16, 2026, generating approximately $243,000 at a price of $5.84 per share. The transaction, disclosed via a SEC Form 4 filing, accounted for 2.21% of Raab's direct ownership in the company at the time, reducing his holdings to 1,816,448 shares post-sale. The shares sold were sourced from direct ownership following the exercise of 20,833 stock options, with no indirect holdings or gifts involved in the transaction. Raab also retains 25,364 shares indirectly and 374,168 stock options that could be converted to common stock for future liquidity. The sale was conducted under a 10b5-1 trading plan, a prearranged strategy used by insiders to mitigate perceptions of market timing. This transaction follows a similar trade executed by Raab in February 2026. Ardelyx, a biotechnology firm focused on therapies for gastrointestinal and cardiorenal diseases, has seen its stock rise 6.8% year-over-year as of March 16, 2026, but has declined 16.57% over the past five years. The company recently appointed Dr. Rajani Dinavahi as Chief Medical Officer, signaling a potential shift in clinical strategy. Legal challenges, including a 2024 class-action lawsuit related to Medicare program claims for Xphozah, appear to be subsiding after investors dropped their appeal in March 2026. Analysts from Zacks have set an average price target of $16.10 for Ardelyx stock, implying a potential 170% upside from the $5.84 price point at the time of Raab's sale.

Sign up free to read the full analysis

Create a free account to unlock full AI-curated market articles, personalized alerts, and more.

Create Free Account Already have an account? Sign In
Share this article

Related Articles

Score 55 Bullish

Novo Nordisk CEO says weight-loss drug boom has barely begun

Apr 05, 12:27

Score 65

Foxconn Q1 revenue jumps 30% on AI tailwinds; cautions on Middle East "volatility"

Apr 05, 09:11

Stay Ahead of the Markets

Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.

Get Started Free View Plans
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile